Pharmos deal

Pharmos Corp. (PARS) PARS signed a letter of intent under which Bausch & Lomb's pharmaceutical subsidiary will market Lotemax, PARS's site specific ocular anti-inflammatory, in the U.S. Bausch & Lomb...